Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + chemotherapy with differential radiotherapy followed by surgery/radiotherapy in unresectable N2b stage IIIB NSCLC
ChiCTR2600122759Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: 1-year event-free survival rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600122759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122759.